New evidence from BC Children’s Hospital and University of British Columbia (UBC) researchers shows babies can safely be treated for peanut allergies.
Flow cytometry is a technology that can be used to rapidly analyze physical and chemical properties of individual cells. It is a powerful tool with many applications in multiple disciplines such as blood cancers, immunology, molecular biology, and cellular therapy. For example, it is very effective for the study of the immune system and its response to infectious diseases and cancer.
Circulating rhabdoid tumor cells in the peripheral blood of a neonate
American Journal of Hematology
Maryam Al-Bakri and Jefferson Terry and Kate Chipperfield and Douglas Morrison and Audi Setiadi
Malignancy-associated haemophagocytic lymphohistiocytosis
The Lancet Haematology
Audi Setiadi and Adi Zoref-Lorenz and Christina Y Lee and Michael B Jordan and Luke Y C Chen
Targeted treatment of immune thrombocytopenia in CTLA-4 insufficiency: a case report
British Journal of Haematology
Lai, C.M.B. and Setiadi, A. and Barlas, A. and Kanani, A. and Pourshahnazari, P. and Leitch, H.A. and Metzger, D.L. and Merkeley, H. and Biggs, C.M.
Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia
Cytometry Part B - Clinical Cytometry
McGinnis, E. and Yang, D. and Au, N. and Morrison, D. and Chipperfield, K.M. and Setiadi, A.F. and Liu, L. and Tsang, A. and Vercauteren, S.M.
The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia
International Journal of Laboratory Hematology
A. Setiadi and D. Owen and A. Tsang and R. Milner and S. Vercauteren
Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase.
Differential regulation of transforming growth factor beta signaling pathways by Notch in human endothelial cells.
The Journal of biological chemistry
Minimal Residual Disease & Leukemic Stem Cells
Minimal residual disease refers to a small number of malignant cells that remain in the patient during or after treatment when the patient has no signs or symptoms of the disease. Flow cytometry allows for MRD analysis by looking at different expression of cellular antigens on malignant cells compared to normal cells. As part of Dr. Suzanne Vercauteren’s team, our lab has implemented 10-color flow cytometry panels for MRD detection in B-cell acute lymphoblastic leukemia (the most common type of blood cancer in children) post chemotherapy and post CD19 directed therapy. In collaboration with the BRAVe initiative, we are currently looking at more markers to identify leukemic stem cell populations, which may contribute to relapse or treatment resistance.
Primary Immunodeficiency Disorders and Hemophagocytic Lymphohistiocytosis
PIDDs are a heterogeneous group of inherited disorders resulting from genetic defects that impair the immune system. Given the complexity of the immune system, the clinical manifestations of PIDDs are highly variable and may present with recurrent infections, autoimmunity and predisposition to cancer. Under the “Diseases of Immune Dysregulation” group of PIDD is a life threatening disorder called Hemophagocytic Lymphohistiocytosis (HLH), leading to an overactive, dysfunctional response of immune system, low blood cell counts and multi-organ damage. Our lab implemented clinical flow cytometry panels to support newborn screening for severe combined immunodeficiency (SCID) and expand the investigation for PIDD, as well as Perforin assay for screening of primary HLH. We continue to optimize our assay methodologies and reference ranges to support the diagnosis of PIDD in BC.
Our lab is validating several flow cytometry panels for product assessment of several graft engineering projects under TRACE initiative, including T-cell alpha/beta depleted stem cell transplantation to reduce GvHD risk, as well as viral specific T-cell therapy for severe protracted viral infection post-transplant.Research Group Members
Michelle Dittrick, Clinical Research Program Manager
Lorraine Liu, Clinical flow core manager